Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load.

Internal medicine (Tokyo, Japan) - 1 Jan 2009

Arase Yasuji, Suzuki Fumitaka, Akuta Norio, Sezaki Hitomi, Suzuki Yoshiyuki, Kawamura Yusuke, Kobayashi Masahiro, Hosaka Tetsuya, Yatsuji Hiromi, Hirakawa Miharu, Saito Satoshi, Ikeda Kenji, Kobayashi Mariko, Kumada Hiromitsu

Abstract excerpt

OBJECTIVE: The aim of this study was to evaluate the efficacy of combination therapy of peginterferon and ribavirin in patients infected with hepatitis C virus (HCV) genotype 1b and low virus load. METHODS: Inclusion criteria were HCV-genotype 1b, serum HCV RNA level of < 100 KIU/mL at the initiation time of treatment. A total of 60 were enrolled in this retrospective cohort study. The treatment period of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Multivariate Analysis

Share to Polyethylene Glycols

Share to Ribavirin

Share to Viral Load

Source

Identifiers

PMID: 19252344
DOI: 10.2169/internalmedicine.48.1629

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load.PMID 19252344Read ↗

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load.Semantic proximity Read ↗

A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C.Semantic proximity Read ↗

Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load.Semantic proximity Read ↗

Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load.Semantic proximity Read ↗

Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads.Semantic proximity Read ↗

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.Semantic proximity Read ↗

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.Semantic proximity Read ↗

Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.Semantic proximity Read ↗

Therapy of chronic hepatitis C: a critical review.Semantic proximity Read ↗

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load.Semantic proximity Read ↗

Changes in serum levels of hepatitis C virus genotype 1b monitored by real-time quantitative polymerase chain reaction as a predictor of long term response to interferon-alpha treatment.Semantic proximity Read ↗

Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.